Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20265 Citations
Bronchogen4 residuesAEDLEach bubble = one amino acid. Size = residue mass. Color = chemical class.Bronchogen (AEDL) is a Khavinson tetrapeptide bioregulator targeting bronchial and pulmonary tissue through gene expression modulation. Rat COPD studies showed epithelial remodeling reversal after 30-day oral courses. No human trials exist. Oral capsule format at 10 to 20 mg daily, cycled every 4 to 6 months per standard bioregulator protocol.
10mcg · Daily
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | Daily |
Bronchogen is oral, so there's no reconstitution math for the standard protocol. Take 1 to 2 enteric-coated capsules (10 to 20 mg each) on an empty stomach, 15 to 20 minutes before breakfast. Swallow whole with water. Don't crush or open them; the enteric coating protects the peptide from gastric acid proteolysis. Without it, the tetrapeptide gets digested before reaching the small intestine. If you're using the injectable research vial route (no published basis, community convention only): reconstitute a 20 mg vial with 10 mL bacteriostatic water for a 2 mg/mL (2000 mcg/mL) concentration. At a 200 mcg dose, that's 10 units on a U-100 insulin syringe. At 500 mcg, that's 25 units. The non-obvious thing most beginners miss: don't expect to feel anything during the course. The proposed mechanism is epigenetic. Any subjective benefits, if they exist, typically show up weeks to months after finishing a course. Repeating courses more often than every 4 months overlaps the residual effect window and adds cost without documented extra benefit.
Dosing based on Khavinson Institute protocol — 10 published references.View all sources →
Cross-check your Bronchogen reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Bronchogen (AEDL) is a Khavinson tetrapeptide bioregulator targeting bronchial and pulmonary tissue through gene expression modulation. Rat COPD studies showed epithelial remodeling reversal after 30-day oral courses. No human trials exist. Oral capsule format at 10 to 20 mg daily, cycled every 4 to 6 months per standard bioregulator protocol.
